NET ASSET VALUE – 30 September 2024
On the 30 September 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,262 million and NAV per share was SEK 54.59.
|
Allocation of NAV |
Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 475 | 6.09 | 11.1% |
| Xspray Pharma | 18% | 294 | 3.77 | 6.9% |
| Empros Pharma | 79% | 204 | 2.62 | 4.8% |
| KAHR Medical | 31% | 191 | 2.44 | 4.5% |
| Atrogi | 37% | 176 | 2.25 | 4.1% |
| Xintela | 56% | 165 | 2.11 | 3.9% |
| Lipum | 57% | 164 | 2.10 | 3.8% |
| Microbiotica | 11% | 135 | 1.73 | 3.2% |
| Geneos Therapeutics | 12% | 97 | 1.24 | 2.3% |
| Mendus | 24% | 96 | 1.23 | 2.3% |
| EpiEndo Pharmaceuticals | 9% | 56 | 0.72 | 1.3% |
| Toleranzia | 58% | 56 | 0.71 | 1.3% |
| Synerkine Pharma | 43% | 52 | 0.67 | 1.2% |
| AnaCardio | 19% | 52 | 0.66 | 1.2% |
| Egetis Therapeutics | 2% | 37 | 0.47 | 0.9% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 23% | 26 | 0.33 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Vitara Biomedical | 5% | 13 | 0.17 | 0.3% |
| Amarna Therapeutics | 58% | 11 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,354 | 30.16 | 55.2% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.4% |
| Symcel | 31% | 169 | 2.16 | 4.0% |
| Chromafora | 31% | 73 | 0.93 | 1.7% |
| Provell Pharmaceuticals | 72% | 69 | 0.88 | 1.6% |
| A3P Biomedical | 8% | 42 | 0.54 | 1.0% |
| Nanologica | 39% | 39 | 0.50 | 0.9% |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.4% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 616 | 7.89 | 14.5% | |
| Limited Partnerships, total | 92 | 1.18 | 2.2% | |
| Assets related to Portfolio companies | 289 | 3.70 | 6.8% | |
| Other assets and liabilities | 910 | 11.66 | 21.4% | |
| NAV | 4,262 | 54.59 | 100.0% | |
* indirect shares in Provell Pharmaceuticals